Frelii Discusses Medical Cannabis and Artificial Intelligence with Canada Prime Minister Justin Trudeau

Frelii CEO, Ian Jenkins (Right) met Canada Prime Minister, Justin Trudeau (Left). Discussion included how AI and DNA analysis can advance the medical cannabis industry. (Photo: Business Wire)

LEHI, Utah--()--Ian Jenkins, CEO of Frelii Inc. (OTCQB: FRLI) (“Frelii” or “The Company") met in an informal meeting with Canadian Prime Minister, Justin Trudeau to discuss how Frelii’s artificial intelligence (AI) technology could be beneficial in advancing the safe and more effective use of medical cannabis products in Canada.

“This was our first opportunity to meet with the prime minister,” said Ian Jenkins, CEO of Frelii Inc. “Frelii has been working with regulatory officials and physicians in Canada to prepare to deploy our AI technology there. It is designed to enable medical professionals and their patients to use cannabis products, such as CBD, more safely and effectively than the current, trial-and-error approach.”

The use of marijuana for medical purposes has been legal in Canada since 2001. In 2018, the country became the first major world economy to legalize recreational marijuana. Because of its national laws and relaxed regulations, the country is better suited at this time for use of this technology than other countries with more prohibitive laws.

“It is my opinion that Canada would be an ideal epicenter of initial wide deployment of our technology,” Jenkins said. “The environment is primed for expansion as the government was the first to deregulate the whole CBD space. We will be able to grow in an environment where the regulations support the expansion of a responsible approach for the safe consumption of cannabis products. Mr. Trudeau said he was encouraged that Frelii was going to deploy its technology there and opened the door for introductions to the minister of innovation, science and economic development, Navdeep Bains.”

Jenkins added that the Prime Minister welcomed the opportunity for Frelii to look at Canada as a venue to expand into.

About Frelii Inc.

Frelii Inc. is a medical technology company that uses gene sequencing and artificial intelligence to determine risk and lifestyle modifications. Its technology analyzes the most comprehensive markers (60,000,000+) on the market to date. Frelii’s technology generates accurate and profoundly valuable insight into DNA. It opens opportunities never before realized in health care, precision medicine, insurance, corporate wellness as well as personal health and risk identification. For more information, please visit www.frelii.com. Frelii (OTCQB: FRLI) trades on the #OTCQB Venture Market for early stage and developing U.S. and international companies. Companies are current in their reporting and undergo an annual verification and management certification process. Investors can find Real-Time quotes and market information for the company on www.otcmarkets.com.

Follow Frelii online at:

Frelii Facebook Page https://www.facebook.com/livefrelii/
Frelii Twitter Feed @livefrelii
Frelii Instagram Page @livefrelii
Frelii LinkedIn Page linkedin.com/company/frelii/

Safe Harbor Statement:

This release contains certain “forward-looking statements” relating to the business of the Company. All statements, other than statements of historical fact included herein are "forward-looking statements" including statements regarding: the continued growth of the e-commerce segment and the ability of the Company to continue its expansion into that segment; the ability of the Company to attract customers and partners and generate revenues; the ability of the Company to successfully execute its business plan; the business strategy, plans, and objectives of the Company; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume any duty to update these forward-looking statements.

Contacts

Media Contact:
Tim Rush
Springboard5
801-208-1100
tim.rush@springboard5.com

Release Summary

Ian Jenkins, CEO of Frelii Inc. met Canadian Prime Minister to discuss how Frelii’s AI technology could help Canada's medical cannabis industry.

Contacts

Media Contact:
Tim Rush
Springboard5
801-208-1100
tim.rush@springboard5.com